[01] Moawia E. Hummeida, Department of Obstetrics and Gynaecology, Division of Gyno-oncology, School of Medicine, Alneelain University, Khartoum, Sudan. [02] Howaida Sharif, Department of Obstetrics and Gynaecology, Khartoum Teaching Hospital, Khartoum, Sudan. [03] Duria A. Rais, Department of Obstetrics and Gynaecology, Faculty of Medicine, Khartoum University, Khartoum, Sudan. [04] Khalid Yassin, Department of Obstetrics and Gynaecology, School of Medicine, Alneelain University, Khartoum, Sudan. [05] Azza Zulfo, Department of Pathology, Khartoum Teaching Hospital, Khartoum, Sudan. [06] Kamal Hamad, Department of Clinical Oncology, Faculty of Medicine, Khartoum University, Khartoum, Sudan. [07] Abdel Aziem A. Ali, Department of Obstetrics and Gynaecology, Faculty of Medicine, Kassala University, Kasala, Sudan.

This was a prospective observational comparative hospital based study conducted in Khartoum Teaching Hospital, Sudan, during September 2011 and through February 2012, to evaluate the role of neoadjuvant chemotherapy (Paclitaxil and carboplatin) in the management of advanced ovarian cancer compared to primary surgery, and to determine the impact of neoadjuvant chemotherapy on the optimization of cytoreductive surgery. Chi-squaire and t tests were performed and P<0.05 was considered significant. A total of fifty patients were enrolled in this study, twenty patients received neoadjuvant chemotherapy and interval debulking surgery (IDS), and 30 patients underwent primary surgery (PS) and received adjuvant chemotherapy. In comparison with patients who received neoadjuvant chemotherapy there was higher proportion of patients showed intra-operative ascites (93.3% Vs 10%, P=<0.001), adhesion (66.6% Vs 0%, P=0.002), omental cake (53.3% Vs 15%, P=0.006) and distant metastasis (93.3% Vs 0%, P=<0.001) among the women who underwent primary surgery. This study showed optimal cyto-reductive surgery for the patients who received neoadjuvant chemotherapy in comparison with those who underwent primary surgery (100% Vs 50%, P=<0.001). The mean (SD) of hospital stay, ICU admission and units of blood transfusion was lower among patients who received neoadjuvant chemotherapy. Thus neoadjuvant chemotherapy is of more benefit than primary surgery in the management of advanced stage ovarian cancer.

Ovarian, Cancer, Chemotherapy, Sudan

[01] Siegel R, Ward E, Beawley O,Jamal A: The impact of eliminating socioeconomic and racial disabilities on premature cancer death.CA cancer J clic 2011,62:212 [02] Markman M: Concept of optimal ctytoreduction in advanced ovarian cancer: a brief action. J clin Oncol 2007, 25: 4168-70. [03] Mazzeo M, Berliere and Kerger et al: Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarly unresected, advanced ovarian cancer. Gynecol Oncol 2003,90: 136-169. [04] Vrscaj MU, S. Rakar S: Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a retrospective case control study. Eur J Gynaecol Oncol 2002, 23: 405-410 [05] Daly m, Abrams GI: Epidemiology and risk assessment of ovarian cancer. Semin Oncol 1998, 25: 255-64. [06] Petru E, Luck HJ, Stuart G:Gynecologic cancer intergroup (GCIG), proposal for change of the current FIGO staging system. Eur J Obstet Gynecol report Biol 2009, 143:69-74 [07] Hennessy BT, Coleman RL, Markman M: Ovarian cancer.Lancet 2009, 374:1371-82. [08] Bristow RE, Duscka L, Lambrou N, et al: A model of predicting surgical outcome in patients with advanced ovarian carcinoma using CT. Cancer 2000, 89:1532-40. [09] Vergote I, De Wever I, Tjalma et al: Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients. Gynecol Oncol 1998,431-436 [10] Nelson BE, Rosenfeld AT, Schwardz PE: Preoperative abdominopelvic CT prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol. 1993, 11:166-72 [11] Camaci A, Balat O:Neoadjuvant chemotherapy in ovarian cancer. Eur Gynecol Oncol. 2002, 23: 437-441. [12] Torres JC,Derchain SF, Faundes A, Gontijo RC, Martinez EZ, Andrade LA:Risk of malignancy index in preoperative evaluation of clinically ovarian cancer. Sao Paulo Med J 2002, 120:72-6 [13] Huober A, Meyer U, Wagner A and Wallwiener D: The role of neoadjuvant chemotherapy and interval Laparotomy in advanced ovarian cancer.J Cancer Res Clinc 2000,128: 153-160. [14] Jamal A, Thomas a, Murray T, Thun M: Critique, and a call for change.Cancer statistics 2002. CA Cancer J 2002, 52:32-47. [15] Cawford SC, Vasey PA, Paul Jay et l: Does aggressive surgery only benefit patientswith less advanced ovarian cancer? Results from international comparison within the SCOTROC1, trial.J L Cline Oncol 2005, 23:8802-11. [16] Morice P, Brehier Olive D, Rey A, et al:Results of interval debulking surgery in advanced stage ovarian cancer: an exposed non exposed study. Ann Oncol. 2003, 14:74-77. [17] Le T, Giede C, Salem S, Lefebvre G et al: Society of Obstetrician and Gynaecologists of Canada. Initial evaluation and referral guidelines for management of of Pelvic/ovarian masssses. J Obstet Gynaecol Can 2009, 31:668-80.